AMY TACKEL: Open Payments
NPI 1194260828 · MANSFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,156 in 65 payments from 22 companies in 2025. Trend: 2023 $2,423 · 2024 $1,691 · 2025 $1,156
Food & beverage: $1,156
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $170 |
| Novo Nordisk Inc | 11 | $166 |
| GlaxoSmithKline, LLC. | 7 | $162 |
| Lilly USA, LLC | 10 | $148 |
| AstraZeneca Pharmaceuticals LP | 4 | $59 |
| Eisai Inc. | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| SANOFI-AVENTIS U.S. LLC | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $37 |
| ABBVIE INC. | 2 | $34 |
Products named: JARDIANCE, TRELEGY ELLIPTA, Ozempic, Leqembi, MOUNJARO, REXULTI, AIRSUPRA, TZIELD.
Industry payments across TX — which companies pay providers there.
